Entecavir
- Generic Name
- Entecavir
- Brand Names
- Baraclude, Entecavir Viatris (previously Entecavir Mylan), Entecavir Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C12H15N5O3
- CAS Number
- 142217-69-4
- Unique Ingredient Identifier
- NNU2O4609D
- Background
Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
...
- Indication
For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
A Study to Assess DV-601 in Subjects With Chronic Hepatitis B
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 14
- Registration Number
- NCT01023230
- Locations
- 🇵🇱
Collegium Medicum Uniwersytet im. Mikołaja Kopernika, Bydgoszcz, Poland
🇵🇱NZOZ Centrum Badan Klinicznych, Wrocław, Poland
🇵🇱Wojewódzki Szpital Zakaźny, Warsaw, Poland
A Phase II Dose Response Study in Japan in Chronic Hepatitis B
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT01022801
A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2010-08-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT01020565
Arabinoxylan Rice Bran (MGN-3/Biobran) for the Treatment of Hepatocellular Carcinoma and Hepatitis B and C Infection
- Conditions
- Interventions
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- The 108 Military Central Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT01018381
- Locations
- 🇻🇳
The 108 Military Central Hospital, Hanoi, Vietnam
Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 50
- Registration Number
- NCT01013272
- Locations
- 🇨🇳
The University of Hong Kong, Hong Kong, China
Simvastatin for the Treatment of Chronic Hepatitis B
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2012-08-16
- Lead Sponsor
- Bader, Ted, M.D.
- Target Recruit Count
- 32
- Registration Number
- NCT00994773
- Locations
- 🇺🇸
VA Medical Center, Oklahoma City, Oklahoma, United States
Entecavir Plus Adefovir in Lamivudine-Resistant Patients
- Conditions
- Interventions
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00986778
Continue Entecavir Rollover From China
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 600
- Registration Number
- NCT00975091
A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2016-03-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT00940485
Incidence of Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2016-11-09
- Lead Sponsor
- National Health Research Institutes, Taiwan
- Target Recruit Count
- 202
- Registration Number
- NCT00931229
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.